Increased Serum Creatinine Reversible Upon Imatinib Discontinuation

Share this content:
Imatinib increased serum creatinine by reducing its tubular secretion, a previously unreported pharmacologic property of the kinase inhibitor.
Imatinib increased serum creatinine by reducing its tubular secretion, a previously unreported pharmacologic property of the kinase inhibitor.

Imatinib increased serum creatinine by reducing its tubular secretion, a previously unreported pharmacologic property of the kinase inhibitor, a study published in the journal Clinical Lymphoma, Myeloma, & Leukemia has shown.1

Because serum creatinine may increase over the course of imatinib therapy, it is important for clinicians to monitor renal function in patients receiving imatinib for chronic myeloid leukemia (CML); however, the mechanism of this increase and its reversibility on treatment discontinuation remain unknown.

For the study, researchers retrospectively analyzed data from imatinib-treatment patients. The glomerular filtration rate, urinary clearance, and tubular secretion of creatinine of patients were compared with those of matched controls. Researchers also evaluated variations of serum creatinine before and during imatinib discontinuation and after imatinib resumption in patients enrolled in imatinib discontinuation studies.

Results showed that in 4 patients treated with imatinib, the part of creatinine clearance due to tubular secretion was negligible. Further, researchers found that this was significantly lower than that measured in their respective controls (P < .001).

RELATED: Lymphocytosis Linked With Improved Outcomes in Dasatinib-treated Patients With CML

In terms of reversibility, researchers observed a median decrease of nearly 18% in serum creatinine after imatinib cessation in 15 patients from imatinib discontinuation studies. The study demonstrated that when treatment was resumed in 6 patients, there was a median increase in serum creatinine of almost 19%.

The findings suggested that increases in serum creatinine are fully reversible upon imatinib cessation.

Reference

  1. Vidal-Petiot E, Rea D, Serrano F, et al. Imatinib increases serum creatinine by inhibiting its tubular secretion in a reversible fashion in chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2016;16(3):169-174.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters